Neuroendocrine activity in untreated heart failure.

J Remes, I Tikkanen, F Fyhrquist, K Pyörälä

Kuopio University, Central Hospital, Finland.

Neuroendocrine activity was studied in 60 consecutive untreated patients with dyspnoea and a clinical suspicion of heart failure. On the basis of the so-called Boston clinical criteria the diagnosis of heart failure was regarded as unlikely in 26 patients, possible in 15 patients, and definite in 19 patients. These groups were studied before any drug treatment was started and were compared with a control group of 69 healthy individuals. Plasma atrial natriuretic peptide concentration was clearly raised in patients with definite heart failure and slightly raised in patients with possible heart failure. Plasma adrenaline concentration was somewhat raised in patients with definite or possible heart failure, whereas plasma noradrenaline concentration was raised only in patients with definite heart failure. Plasma renin activity was not increased in any of the patient groups and plasma aldosterone concentration was slightly increased only in patients with definite heart failure. In the total patient series there were significant correlations between plasma atrial natriuretic peptide concentration and markers of the severity of left ventricular dysfunction. There was some evidence of neuroendocrine activation in untreated heart failure: plasma concentrations of atrial natriuretic peptide and catecholamines were increased but the renin-angiotensin-aldosterone system showed little or no activation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Mikkelsen, K. V., Moller, J. E., Bie, P., Ryde, H., Videbaek, L., Haghfelt, T. (2006). Tei index and neurohormonal activation in patients with incident heart failure: Serial changes and prognostic value. Eur J Heart Fail 8: 599-608 [Abstract] [Full Text]  
• Dagenais, G. R., Yusuf, S., Bourassa, M. G., Yi, Q., Bosch, J., Lonn, E. M., Kouz, S., Grover, J. (2001). Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study. Circulation 104: 522-526 [Abstract] [Full Text]  
• Cheng, V., Kazanagra, R., Garcia, A., Lenert, L., Krishnaswamy, P., Gardetto, N., Clopton, P., Maisel, A. (2001). A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37: 386-391 [Abstract] [Full Text]  
• Klemola, R., Tikkanen, I., Vuolteenaho, O., Toivonen, L., Laine, M. (2001). Plasma and pericardial fluid natriuretic peptide levels in postinfarction ventricular dysfunction. Eur J Heart Fail 3: 21-26 [Abstract] [Full Text]  
• Maeda, K., Tsutamoto, T., Wada, A., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., Kinoshita, M. (2000). High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36: 1587-1593 [Abstract] [Full Text]  
• Kataoka, H., Takada, S. (2000). The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure. J Am Coll Cardiol 35: 1638-1646 [Abstract] [Full Text]  
• Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., Ohnishi, M., Sawaki, M., Fujii, M., Matsumoto, T., Kinoshita, M. (2000). Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35: 714-721 [Abstract] [Full Text]  
• Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Mabuchi, N., Hayashi, M., Ohnishi, M., Sawaki, M., Fujii, M., Horie, H., Sugimoto, Y., Kinoshita, M. (1999). Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20: 1799-1807 [Abstract]  
• Stanford, S. C., Salmon, P., Mikhail, G., Gettins, D., Zielinski, S., Pepper, J. R. (1999). Plasma catecholamines, pharmacotherapy and mood of subjects with cardiovascular disorder. J Psychopharmacol 13: 255-260 [Abstract]  
• Chatelain, R. E., Ghai, R. D., Trapani, A. J., Odorico, L. M., Dardik, B. N., De Lombaert, S., Lappe, R. W., Fink, C. A. (1998). Antihypertensive and Natriuretic Effects of CGS 30440, a Dual Inhibitor of Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11. J. Pharmacol. Exp. Ther. 284: 974-982 [Abstract] [Full Text]  
• Tsutamoto, T., Wada, A., Maeda, K., Hisanaga, T., Maeda, Y., Fukai, D., Ohnishi, M., Sugimoto, Y., Kinoshita, M. (1997). Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction. Circulation 96: 509-516 [Abstract] [Full Text]